Latest News and Press Releases

Reference is made to the notice of 4 November 2016 regarding the board of directors' resolution to increase the share capital in Targovax ASA (the "Company") in connection with the exercise of...

Reference is made to stock exchange notice of 4 November 2016 regarding increase of the share capital in Targovax ASA (the "Company") relating to exercise of employee options and settlement of...

Jon Amund Eriksen, Chief Technology Innovation Officer of Targovax ASA, has on 17 November 2016 acquired 3,951 shares in Targovax ASA at a price of NOK 9.60 per share. Following the transaction, Jon...

OSLO, Norway, Nov. 17, 2016 (GLOBE NEWSWIRE) -- Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target,...

OSLO, Norway, Nov. 16, 2016 (GLOBE NEWSWIRE) -- Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target,...

Extends protection following grant of ONCOS-102 US patent in May Oslo, Norway, Nov. 10, 2016 (GLOBE NEWSWIRE) -- Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company...

OSLO, Norway, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Targovax ASA (OSE: TRVX), a clinical stage company focused on developing and commercializing immuno-oncology therapies to target, primarily,...

The board of directors of Targovax ASA (the "Company") has on 3 November 2016, in accordance with the authorisations granted by the general meeting 13 April 2016, resolved: to increase the share...

OSLO, Norway, Nov. 2, 2016 (GLOBE NEWSWIRE) -- Targovax ASA ("Targovax" or "the Company"; OSE:TRVX), a clinical stage company focused on developing and commercializing immuno-oncology therapies to...

OSLO, Norway, Oct. 17, 2016 (GLOBE NEWSWIRE) -- Targovax (OSE: TRVX, or "the Company"), a clinical stage company developing targeted immunotherapy treatments for cancer patients, announces that the...